Ann Louise Merchant - 18 Mar 2026 Form 3 Insider Report for Biodexa Pharmaceuticals Plc (BDRX)

Role: Director
Signature: /s/ Fiona Mary Powell, Attorney-in-Fact
Issuer symbol: BDRX
Transactions as of: 18 Mar 2026
Net transactions value: $0
Form type: 3
Filing time: 18 Mar 2026, 09:30:20 UTC
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Merchant Ann Louise	Director	C/O BIODEXA PHARMACEUTICALS PLC, 1 CASPIAN POINT, CASPIAN WAY, CARDIFF, UNITED KINGDOM	/s/ Fiona Mary Powell, Attorney-in-Fact	18 Mar 2026	0002116561

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	BDRX	Stock Option (right to buy)							18 Mar 2026	American Depositary Shares	288	$475.00	Direct	F1, F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares underlying this option vest over a four-year period with (i) 25% vesting on the one-year anniversary of grant, and (ii) 6.25% vesting every three months thereafter, subject to the Reporting Person's continued service through the applicable vesting date.
F2	Each American Depositary Share represents 100,000 ordinary shares, nominal value PS0.000001 per share, of the Issuer.
F3	The exercise price for this option is denominated in British pounds sterling at a price of GBP 373.936 per American Depositary Share. The exercise price reported herein was converted into British pound sterling to United States dollars at a conversion rate of GBP 1.00 to USD 1.2703. The exercise price is the actual British pound sterling amount regardless of the exchange rate on the date of exercise.

Remarks:

Exhibit 24.1 -- Power of Attorney